Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method

• US 6,841,542 B2
• Filed: 07/06/2001
• Issued: 01/11/2005
• Est. Priority Date: 07/06/2000
• Status: Expired due to Term

• Current Assignee: Sarepta Therapeutics, Inc.
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Bartelmez, Stephen H., Iversen, Patrick L.
• Primary Examiner(s): McGarry, Sean
• Application Number:
  US09/900,115
• Publication Number:
  US 20030109465A1
• Time in Patent Office: 1,285 Days
• Field of Search: 435/325, 435/377, 435/375, 514/44, 536/23.1, 536/24.1, 536/24.5
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2310/314 Phosphoramidates
• CPC Class Codes: C12N 2310/3233 Morpholino-type ring
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

The invention relates to TGF-β blocking agent-treated HSC compositions and methods comprising the same. The TGF-β blocking agent-treated stem cells are viable for an extended time in culture without replication or differentiation and upon transfer to appropriate conditions are capable of long term hematopoietic reconstitution.

Claims

1. A method of decreasing the time for hematopoietic reconstitution of a patient following chemotherapy or radiation therapy, comprising:

(a) obtaining a population of cells containing human stem cells from a subject;

(b) enriching for the human stem cells in said population;

(c) exposing the enriched stem cell population, ex vivo, to an oligomer antisense to TGF-β

, under culture conditions and for a period of time effective to block the effect of TGF-β

on replication and/or differentiation of said stem cells;

(d) culturing the antisense oligomer treated stem cells to obtain cultured TGF-β

blocking agent-treated stem cells, wherein the viability and differentiation state of said stem cells is maintained for at least 5 days; and

(e) administering said cultured TGF-β

blocking agent-treated stem cells to a subject, wherein the time required for in vivo reconstitution of at least one hematopoietic lineage is reduced relative to that of a subject who received stem cells not treated with an oligomer antisense to TGF-β

.

2. The method of claim 1, wherein the human stem cells in said enriched stem cell population are characterized as lacking the expression of lineage markers (lin-), and are either (a) positive for cell surface expression of CD 34 and KDR and negative for cell surface expression of CD38 or (b) positive for cell surface expression of both CD 34 and Thy1.

3. The method of claim 1, wherein the antisense oligomer is a morpholino oligomer characterized by,

(a) a backbone which is substantially uncharged;

(b) the ability to hybridize with the complementary sequence of a target RNA with high affinity at a Tm greater than 50°

C.;

(c) nuclease resistance; and

(d) the capability for active or facilitated transport into cells.

4. The method of claim 3, wherein the linkage is a phosphorodiamidate linkage represented at FIG. 2B, where X═

NH₂, Y═

O, and Z═

O.

5. The method of claim 3 wherein the antisense oligomer has a length of from 12 to 25 bases.

6. The method of claim 4 wherein the antisense oligomer has a sequence presented as SEQ ID NO:

1, SEQ ID NO;

2 or SEQ ID NO;

5.